drugset / Trial / NCT06650488

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

NCT06650488

Phase 4 Recruiting 300 enrolled Todd C. Lee MD MPH FIDSA
RandomizedParallel-groupSingle-blindTreatment

Summary

This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention. Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119). If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.

Timeline

Start
2026-01-15
Primary completion
2030-01
Completion
2030-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule
Subject Clopidogrel Small molecule